Marcello Carotti

TL;DR: The results were compared to those gained from a parallel analysis of the bacterial (Streptomyces antibioticus) enzyme and those acquired from the literature for mushroom tyrosinase, showing that the reactivity of the human enzyme appears unique and pointing out the great bias introduced when using non-human tyros inases to measure the inhibitory efficacy of new molecules.

TL;DR: This study reveals that HOPNO-embedded 6-hydroxyaurone is to date the most effective inhibitor of isolated human tyrosinase, and could represent a milestone on the path toward new valuable agents in dermocosmetics, as well as in medical fields where it was recently suggested that tyosinase could play key roles.

TL;DR: It is shown that the application of small molecules developed to rescue ΔF508-CFTR trafficking, and known as CFTR correctors, also improved the maturation of several α-sarcoglycan mutants that were consequently rescued at the plasma membrane, the first report showing a quantitative and functional recovery of the sarcoglycan-complex in human pathologic samples, upon small molecule treatment.

TL;DR: Whether estrogenic agents regulate the stability and/or degradation of glycolytic proteins in human umbilical vein endothelial cells (HUVECs) is investigated and the role of USP19 as a target of the pro‐angiogenic effect of estrogenicagents is unraveled.

TL;DR: This work describes the state of the art in the field of treatments for sarcoglycanopathy and presents emerging novel therapeutic strategies explored at the preclinical stage that are expected to replace the defective gene, address general effects of the disease, or address the primary events of the pathogenic mechanism.